{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:00Z","timestamp":1790957880624,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI18C1953"],"award-info":[{"award-number":["HI18C1953"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118289","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:39:02Z","timestamp":1750786742000},"page":"118289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Dual IL-2\/IL-21 priming augments the anti-tumor function of CD16V-CAR\/TRAIL-engineered NK cells in combination with monoclonal antibodies"],"prefix":"10.1016","volume":"189","author":[{"given":"Injung","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118289_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2024.111251","article-title":"Investigation of NK cell function against two target hematological cell line using radioactive chromium assay","volume":"206","author":"Jurisic","year":"2024","journal-title":"Appl. Radiat. Isot."},{"issue":"11","key":"10.1016\/j.biopha.2025.118289_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells12111496","article-title":"Special issue \"new developments in natural killer cells for immunotherapy\"","volume":"12","author":"Zimmer","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2014655","article-title":"Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action","volume":"11","author":"Hwang","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40425-019-0612-2","article-title":"Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy","volume":"7","author":"Yang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118289_bib5","series-title":"Natural Killer Cells","first-page":"169","article-title":"Chapter Twelve - Development and testing of NK cell lines","author":"Klingemann","year":"2010"},{"issue":"7","key":"10.1016\/j.biopha.2025.118289_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1023\/A:1027387930868","article-title":"IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC","volume":"20","author":"Konjevic","year":"2003","journal-title":"Clin. Exp. Metastas."},{"issue":"6","key":"10.1016\/j.biopha.2025.118289_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000382019","article-title":"Human cytokine-induced memory-like natural killer cells","volume":"7","author":"Berrien-Elliott","year":"2015","journal-title":"J. Innate Immun."},{"issue":"9","key":"10.1016\/j.biopha.2025.118289_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","article-title":"A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy","volume":"9","author":"Becker-Hapak","year":"2021","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.biopha.2025.118289_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.omto.2022.02.009","article-title":"A novel fusion protein scaffold 18\/12\/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells","volume":"24","author":"Cubitt","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"9","key":"10.1016\/j.biopha.2025.118289_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00262-024-03765-8","article-title":"A \"Prime and Expand\" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy","volume":"73","author":"Shrestha","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21873\/anticanres.13085","article-title":"Culturing the human natural killer cell line NK-92 in Interleukin-2 and Interleukin-15 - implications for clinical trials","volume":"39","author":"Tornroos","year":"2019","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.biopha.2025.118289_bib12","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118289_bib13","first-page":"115","article-title":"Effect of IL-12 family cytokines on NK92 cells","volume":"51","author":"Ohshima","year":"2017","journal-title":"J. Osaka Dent. Univ."},{"issue":"16","key":"10.1016\/j.biopha.2025.118289_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164129","article-title":"NK cell therapy: a rising star in cancer treatment","volume":"13","author":"Du","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.biopha.2025.118289_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12032-023-02066-x","article-title":"NK cells direct the perspective approaches to cancer immunotherapy","volume":"40","author":"Jalil","year":"2023","journal-title":"Med. Oncol."},{"issue":"52","key":"10.1016\/j.biopha.2025.118289_bib16","doi-asserted-by":"crossref","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"issue":"9","key":"10.1016\/j.biopha.2025.118289_bib18","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118289_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118289_bib20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1535-7163.MCT-15-0937","article-title":"Secretory TRAIL-armed natural killer cell-based therapy: in vitro and in vivo colorectal peritoneal carcinomatosis xenograft","volume":"15","author":"Song","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"15","key":"10.1016\/j.biopha.2025.118289_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34976","article-title":"NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models","volume":"10","author":"Sheedy","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.biopha.2025.118289_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2025.118289_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2025.118289_bib24","article-title":"Advances in CAR-NK cell therapy for hematological malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2025.118289_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcyt.2015.03.603","article-title":"Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy","volume":"17","author":"Yuan","year":"2015","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.biopha.2025.118289_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","article-title":"Multiomic analysis of cytokines in immuno-oncology","volume":"17","author":"Jurisic","year":"2020","journal-title":"Expert Rev. Proteom."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2004.05.011","article-title":"Modulation of TNF-alpha activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibodies","volume":"214","author":"Jurisic","year":"2004","journal-title":"Cancer Lett."},{"issue":"2065","key":"10.1016\/j.biopha.2025.118289_bib29","article-title":"Principal component analysis: a review and recent developments","volume":"374","author":"Jolliffe","year":"2016","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","article-title":"IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118289_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2013.00055","article-title":"Epigenetic regulation of NK cell differentiation and effector functions","volume":"4","author":"Cichocki","year":"2013","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","article-title":"High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy","volume":"120","author":"Rataj","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118289_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4049\/immunohorizons.1700022","article-title":"Transfection of FcgammaRIIIa (CD16) alone can be sufficient to enable human alphabetaTCR T lymphocytes to mediate antibody-dependent cellular cytotoxicity","volume":"1","author":"Ollier","year":"2017","journal-title":"Immunohorizons"},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2010.05.034","article-title":"Overcoming TRAIL resistance in ovarian carcinoma","volume":"119","author":"Bevis","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118289_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bcp.2009.05.016","article-title":"Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs\/Akt-mediated cell survival pathway","volume":"78","author":"Kim","year":"2009","journal-title":"Biochem. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010226","article-title":"Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118289_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","article-title":"The application of natural killer cell immunotherapy for the treatment of cancer","volume":"6","author":"Rezvani","year":"2015","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118289_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy","volume":"23","author":"Siegler","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2025.118289_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fimmu.2020.00812","article-title":"Deciphering natural killer cell homeostasis","volume":"11","author":"Pfefferle","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118289_bib40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-11-253286","article-title":"CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells","volume":"116","author":"Juelke","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","article-title":"Interleukin-21 activates human natural killer cells and modulates their surface receptor expression","volume":"123","author":"Skak","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2025.118289_bib43","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3389\/fimmu.2019.02816","volume":"10","author":"Heinze","year":"2019","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118289_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41417-021-00352-2","article-title":"Cytokine-enhanced cytolytic activity of exosomes from NK Cells","volume":"29","author":"Enomoto","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2567.2007.02675.x","article-title":"Interleukin-21 differentially affects human natural killer cell subsets","volume":"122","author":"Wendt","year":"2007","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118289_bib46","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.biopha.2025.118289_bib47","doi-asserted-by":"crossref","first-page":"37128","DOI":"10.18632\/oncotarget.16201","article-title":"Gene-modified NK-92MI cells expressing a chimeric CD16-BB-zeta or CD64-BB-zeta receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10616-021-00476-1","article-title":"An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16\/CAR","volume":"73","author":"Zhao","year":"2021","journal-title":"Cytotechnology"},{"issue":"23","key":"10.1016\/j.biopha.2025.118289_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells12232748","article-title":"NK92 expressing anti-BCMA CAR and secreted TRAIL for the treatment of multiple myeloma: preliminary in vitro assessment","volume":"12","author":"Motais","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2025.118289_bib50","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3892\/ol.2016.5011","article-title":"Inhibition of gamma-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5","volume":"12","author":"Greene","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2025.118289_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.896228","article-title":"All about (NK Cell-Mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity","volume":"13","author":"Ramirez-Labrada","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118289_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4049\/jimmunol.177.1.120","article-title":"3rd, Interleukin-21 enhances NK cell activation in response to antibody-coated targets","volume":"177","author":"Roda","year":"2006","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118289_bib53","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1078-0432.CCR-16-0004","article-title":"3rd, IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells","volume":"23","author":"McMichael","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.biopha.2025.118289_bib54","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcyt.2014.04.008","article-title":"Effect of exposure to interleukin-21 at various time points on human natural killer cell culture","volume":"16","author":"Lim","year":"2014","journal-title":"Cytotherapy"},{"issue":"ement_1","key":"10.1016\/j.biopha.2025.118289_bib55","article-title":"FT596: translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.biopha.2025.118289_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-142750","article-title":"FT576: multi-specific off-the-shelf CAR-NK cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma","volume":"136","author":"Goodridge","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.biopha.2025.118289_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203488","article-title":"Review of current and future medical treatments in head and neck squamous cell carcinoma","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:53:01Z","timestamp":1754653981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"alternative-id":["S0753332225004834"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118289","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual IL-2\/IL-21 priming augments the anti-tumor function of CD16V-CAR\/TRAIL-engineered NK cells in combination with monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118289"}}